HOME >> BIOLOGY >> NEWS
Drug developed for rare disease may help millions more as treatment for cancer, autoimmune diseases

ANN ARBOR, Mich. An anti-angiogenesis drug developed at the University of Michigan is showing promise in studies of three different disease families, including multiple forms of cancer. The drug, tetrathiomolybdate or TM, essentially wages war against copper, which serves to choke off tumor growth, fibrosis and inflammation.

U-M researcher George Brewer, M.D., who developed the drug, will present his findings to date and report on ongoing basic and clinical TM research at the 226th American Chemical Society national meeting Sept. 10 in New York. Brewer's presentation will be part of a one-day symposium on medicinal inorganic chemistry.

TM began as a treatment for Wilson's disease, a rare genetic disease that causes toxic build-ups of copper. Recent phase III clinical data show TM is more effective than other treatments at reducing the disease's effects. Realizing the key role of copper in angiogenesis, Brewer and colleagues then began exploring treatments for cancer, including breast cancer, kidney cancer and liver cancer. Currently, TM is involved in nine phase II clinical studies related to cancer, with more planned.

But it doesn't end there. Brewer and colleagues are also looking into the effect of TM on inflammatory fibrosis diseases such as pulmonary fibrosis, cirrhosis, cystic fibrosis and psoriasis.

"TM has the potential to be a powerful tool in fighting a wide range of diseases. While it has literally saved the lives of young people with Wilson's disease, Wilson's is a rare disease. If early results in cancer and inflammatory diseases hold their promise through the next phase of trials, there's potential for this to impact a lot of people," says Brewer, Morton S. and Henrietta K. Sellner Emeritus Professor of Human Genetics at the University of Michigan Medical School.

Wilson's disease typically strikes young adults in their teens or early 20s. The condition causes copper to accumulate in the body at dangerous levels,
'"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
10-Sep-2003


Page: 1 2 3 4

Related biology news :

1. Computer database being developed at Temple will allow for better inventory of chemicals
2. New software developed at Rensselaer predicts promising ingredients for new drugs
3. New imaging technique developed to identify breast cancer
4. Portable kidney dialysis machine developed
5. New method of identifying and isolating stem cells developed
6. Study calls for cheaper antitoxins for plant poisoning in less-developed countries
7. Fe-TAML(R) activators developed at Carnegie Mellon remove recalcitrant sulfur from automotive fuels
8. Fe-TAML(R) activators developed at Carnegie Mellon decontaminate anthrax simulant
9. Fe-TAML(R) activators developed at Carnegie Mellon break down toxic pesticides
10. Fe-TAML(R) activators developed at Carnegie Mellon help cleanup paper and wood pulp manufacturing
11. Fe-TAML(R) activators developed at Carnegie Mellon decolorize textile mill wastewater

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
Breaking Biology News(10 mins):
(Date:7/13/2017)... ... July 13, 2017 , ... Heritage Biologics is proud ... the independent leader in promoting healthcare quality through accreditation, certification and measurement. By ... improved processes and better patient outcomes. , “Achieving URAC accreditation is a ...
(Date:7/13/2017)... , ... July 13, 2017 , ... ... two spectrophotometer calibration standards. Blast forward seven years and now they are ... holmium oxide for wavelength accuracy, and resolution testing. , ...
(Date:7/13/2017)... Philadelphia, PA (PRWEB) , ... July 13, 2017 ... ... and business acceleration programs at Philadelphia’s University City Science Center, Christopher Laing, MRCVS, ... innovation zone in Austin, Texas. Dr. Laing will become the first Executive ...
(Date:7/13/2017)... ... ... Microscan , the number-one brand of embedded clinical barcode readers and leading ... platform for barcode reading and machine vision, LVS label verification, and print ... place on August 1–3 in San Diego, CA. , MicroHAWK barcode readers ...
Breaking Biology Technology:
Cached News: